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Abstract
Background: Urinary tract infection is the most common infectious disease requiring hospitalisation following renal
transplantation. However, the risk and outcome of post-transplant pyelonephritis remains unclear.
Methods: This population-based cohort study was conducted from 1 January 1990 to 31 December 2009. Each
member of a Danish population-based, nationwide cohort of first-time renal transplant recipients was matched by
age and gender with up to 19 population controls. Information on hospital discharge diagnosis, emigration, and
mortality was obtained from nationwide administrative databases. Individuals were observed from the date of first
renal transplantation and until graft loss, emigration, or death. Risk factors were assessed by Poisson regression.
Results: The incidence rate (IR) of first-time hospitalisation for pyelonephritis was 18.5 (95 % confidence interval [CI]: 16.4–
20.9) per 1,000 person-years of follow-up (PYFU) among renal transplant recipients (N = 2,656) and 0.26 (CI: 0.21–0.31) per
1,000 PYFU among population controls (N = 49,226) yielding an incidence rate-ratio (IRR) of 72.0 (95 % CI: 57.8–89.7).
Among renal transplant recipients, the risk of pyelonephritis decreased during the entire study period and was lowest in
2005–09 (IRR = 0.46, CI: 0.31–0.68). The highest risk of pyelonephritis was observed within the first six months
post-transplantation (IR = 69.9 per 1,000 PYFU; CI: 56.4–86.7). Other risk factors for post-transplant pyelonephritis included
female gender, high Charlson comorbidity index score, HLA-DR mismatch, cause of renal failure, and calendar period.
Interestingly, we found that the combined risk of graft loss and death was 45 %, (CI: 19–77 %) higher in renal transplant
recipients following post-transplant pyelonephritis compared to those who had no admission due to pyelonephritis.
Conclusions: The risk of first-time hospitalisation for pyelonephritis among renal transplant recipients is high. Further,
post-transplant pyelonephritis was associated with excess risk of graft loss and death; this indicates that strategies aimed
at reducing upper urinary tract infections are likely to enhance renal graft survival.
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Background
Renal transplantation dramatically improves quality of
life and life expectancy compared to conventional
hemodialysis in end-stage renal disease (ESRD). In 2010,
annual renal transplant rates in the United Stated and
Denmark were 57.5 and 41.3 per million population,
respectively [1].
Immunosuppressive therapy in conjunction with per-
and post-operative instrumentation of the urinary tract,
renders renal transplant (RTx) recipients prone to
infectious complications [2]. In addition, RTx recipients
often have various co-morbidities such as cardiovascular
disease and diabetes mellitus, further increasing their risk
of infection.
The most common bacterial infection following renal
transplantation is urinary tract infection (UTI) including
pyelonephritis [3, 4], ranging from 7 to 86 % [5, 6]. The
incidence of UTI among RTx recipients has declined
during the past three decades [7]. However, previous
studies have shown that RTx recipients may have an in-
creased risk of UTI compared to the background popu-
lation [8–10]. It remains controversial whether UTI
causes RTx recipients to be prone to graft loss and/or
associated with an increased mortality rate.
* Correspondence: metgrave@rm.dk
1Department of Infectious Diseases, Aarhus University Hospital, Palle
Juul-Jensens Boulevard 99, 8200 Aarhus N, Denmark
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Graversen et al. BMC Infectious Diseases  (2016) 16:264 
DOI 10.1186/s12879-016-1608-x
The purpose of this nationwide population-based
study was to determine the incidence of pyelonephritis
and to identify risk factors for post-transplant pyelo-
nephritis among RTx recipients and population controls,
as well as to determine impact on graft survival and
mortality in RTx recipients.
Methods
Study design and setting
We conducted a nationwide population based cohort
study among RTx recipients in Denmark between 1990
and 2009. In the study period, treatment of ESRD in
Denmark was offered at 15 specialised nephrology de-
partments of which four performed renal transplanta-
tions. Each department reported data to the Danish
Nephrology Registry (DNR) database [11], which has
collected nationwide data with a completeness of 97.2 %
on patients with ESRD since 1990 [12]. In 2011, the
DNR database included data on approximately 15,000
patients with ESRD of which 4,062 received a renal graft
between 1990 and 2009.
Study population
We identified RTx recipients at 16 years or older receiv-
ing their first transplant after 1 January 1990 in the DNR
database. For each RTx recipient we sampled up to 19
controls matched on gender and age (month and year of
birth) on the day the RTx patient was diagnosed with
ESRD using the Danish Civil Registration System (CRS).
Since 1968, all Danish citizens have been registered in
the CRS [13] encompassing information on date of birth,
age, and gender, through the unique 10-digit civil regis-
tration number (CRN) assigned to each citizen. The CRS
was further used to obtain information on date of migra-
tion and death. The CRN enables accurate linkage across
databases.
Identification of hospitalisation of patients with
pyelonephritis
The Danish National Registry of Patients (DNPR) has
collected data on all patients admitted to Danish somatic
hospitals since 1977. Since 1995, data on attendance to
emergency and outpatient clinics has also been included.
The DNPR contains information on e.g., the CRN, diag-
nosis codes and dates of admission and discharge. Since
1994 the diagnoses have been coded in accordance with
the 10th edition of the International Classification of
Diseases (ICD-10). From 1977 to 1993, the diagnoses
were coded with reference to the 8th edition (ICD-8).
Using data from DNPR, all hospital admissions with a
discharge diagnosis of pyelonephritis with or without
known renal disease were identified. In this study, ICD-8
(59010) and ICD-10 (DN109 and DN129) were used to
identify hospitalisation of patients with pyelonephritis.
Patients with a prior discharge diagnosis of pyeloneph-
ritis were excluded.
Validation of the pyelonephritis diagnosis
To validate the diagnosis of pyelonephritis in the DNPR
we reviewed a representative sample of 75 medical re-
cords from patients with pyelonephritis as the primary
discharge diagnosis in the study period from 1990 to
2009. The reviews were confined to Aarhus University
Hospital, since the data quality in the DNPR is consid-
ered to be uniform throughout the country [14].
Definition of pyelonephritis
Pyelonephritis is a clinical syndrome which lacks a uni-
formly accepted definition.
In the validation process, we used the following cri-
teria to confirm the pyelonephritis diagnosis in the
DNRP (at least one positive finding from each of the
three following categories was required):
1. Positive microbiology or imaging,
a. comprising a urinary stix positive for nitrite and/
or leukocyte esterase and/or a positive urine
culture and/or ultrasound marks indicating
pyelonephritis.
2. Positive laboratory test results
a. including leukocyte count ≥ 12x 109 cells/L and/
or CRP ≥ 80 mg/L and/or temperature > 37.8° .
3. Positive clinical signs,
a. including one or more of the following: graft-
pain/flank pain, chills, clinical symptoms consist-




For patients with ESRD, time at risk was calculated from
the date of first renal transplantation and until graft loss,
lost to emigration, death, or 31 December 2009 (end of
study period), whichever came first. Population controls
entered the study on the same day as their matched RTx
recipient.
Incidence rate, incidence rate-ratio and cumulative
incidence
Four calendar periods were defined (1990–94, 1995–99,
2000–04, and 2005–09) and incidence rates (IRs) of
first-time hospital admission for pyelonephritis were cal-
culated for RTx recipients and population controls for
each of the calendar periods and compared by calculat-
ing the incidence rate-ratio (IRR) with 95 % confidence
intervals (CI). IRRs were calculated for the whole study
period with and without adjustment for comorbidity,
calendar periods, age, and gender.
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The cumulative incidence of first time hospitalisation
for pyelonephritis was calculated for both RTx recipients
and population controls stratified by gender.
Comorbidity data
The Charlson comorbidity index (CCI) score for each
study participant based on the complete hospital dis-
charge history was calculated on the date of their study
entry. The CCI includes 19 major disease categories and
has been adapted and validated for use with hospital dis-
charge data in ICD databases. The CCI is considered a
reliable method for measuring comorbidity in clinical re-
search [15]. In this study, the CCI score did not include
renal disease.
Risk factors
Poisson regression was used to assess risk factors for
first time hospitalisation for pyelonephritis in RTx recip-
ients. The variables included were gender, CCI score
(low (0), medium (1–2), and high (≥3)), donor type (ca-
daveric donor, living unrelated donor, and living related
donor), human leukocyte antigen (HLA) mismatches
(HLA AB mismatches <3/≥3 and HLA DR mismatches
<2/2), cause of ESRD (glomerulonephritis, diabetes mel-
litus types I and II, chronic interstitial nephritis, hyper-
tensive kidney disease, polycystic kidney disease, and
vasculitis), time since transplantation (0–6, 7–12, 13–24,
and >24 months), recipient age (16–49 years, 50–64
years, and ≥65 years), and calendar period.
Mortality and risk of graft loss
We used 90-day mortality to compare survival among
RTx recipients and population controls following diagno-
sis of pyelonephritis. The potential association between
hospitalisation for pyelonephritis and the combined risk of
graft loss and death in RTx recipients was investigated
using poisson regression with pyelonephritis as exposure
(time-varying covariate). To exclude potential bias from
early graft loss, we conducted sensitivity analyses in which
the first 90 days post-transplantation were censored. Both
of these analyses were adjusted for potential confounders
(sex and age).
Stata software, version 11.0 (StataCorp, College Station,
Texas) was used for statistical analyses.
Results
Study population
The study population consisted of 2,656 RTx recipients and
49,226 matched population controls, yielding 14,121 and
447,976 person years of follow-up (PYFU), respectively.
Median follow-up period was 4.3 years for RTx recipients
and 8.7 years for population controls. A first-time hospital-
isation for pyelonephritis was identified in 261 RTx recipi-
ents (9.8 %) and 115 population controls (0.2 %).
Incidence of pyelonephritis
The overall IR of first-time hospitalisation for pyeloneph-
ritis in the entire study period was 18.5 (CI: 16.4–20.9) per
1,000 PYFU among RTx recipients, and 0.26 (CI: 0.21–
0.31) per 1,000 PYFU among population controls. A de-
crease in IR of first-time hospitalisation for pyelonephritis
was observed among RTx recipients from 1990 to 2009,
with a maximum of 30.0 hospitalisations per 1,000 PYFU
(CI: 21.0–42.0) in 1990–94, and a minimum of 14.0 hospi-
talisations per 1,000 PYFU (CI: 11.0–17.0) in 2005–09
(Table 1). The relative risk of hospitalisation for pyeloneph-
ritis among RTx recipients was 0.46 (CI: 0.31–0.68) in
2005–09 compared to 1990–94.
The unadjusted risk of pyelonephritis among RTx re-
cipients was very high compared to population controls
(IRR = 72.0, CI: 57.8–89.7). Adjusting for calendar pe-
riods, age, gender and CCI score, only resulted in a
modest change in the relative risk of pyelonephritis
among RTx recipients (adjusted IRR = 63.9, CI: 50.2–
81.3). The majority of hospitalisations for pyelonephritis
(31.8 %) among RTx recipients were seen within the first
six months post-transplantation.
Impact of comorbidity on risk of pyelonephritis
The risk of first-time hospitalisation for pyelonephritis
was considerably higher in RTx recipients with a medium
or high CCI score than in those with low CCI score
(Table 2). Comparing RTx recipients without comorbidity
(other than ESRD) and population controls without
comorbidity yielded an IRR of 73.5 (CI: 56.1–96.3).
Risk factors for hospitalisation for pyelonephritis among
RTx recipients
In RTx recipients risk factors for first-time hospitalisation
for pyelonephritis in the adjusted analysis were female
gender (IRR = 2.04, CI: 1.59–2.61); high compared to low
CCI-score (IRR = 1.96, CI: 1.16–3.31); HLA-DR mismatch
≥2 vs ≤1 (IRR = 1.54, CI: 1.10–2.18); chronic interstitial
nephritis (IRR = 2.53, CI: 1.66–3.85); hypertensive kidney
disease (IRR = 1.59, CI: 1.06–2.37); polycystic kidney dis-
ease (IRR = 1.66, CI: 1.07–2.57); vasculitis (IRR = 2.61, CI:
1.28–5.30); post-transplant time (compared to 0–6
months: 7–12 months: IRR = 0.39, CI: 0.25–0.59 and 13–
24 months: IRR = 0.24, CI: 0.16–0.37 and + 24 months:
IRR = 0.18, CI: 0.13–0.24); calendar period (compared to
1990–1995: 2000–2004: IRR = 0.62, CI: 0.41–0.94 and
2005–2009: IRR = 0.42, CI: 0.27–0.64) (Table 3).
Mortality and risk of graft loss following hospitalisation
for pyelonephritis
In persons with pyelonephritis, 90-day mortality was
1.5 % (CI: 0.58–4.06 %) for RTx recipients and 1.8 %
(CI: 0.44–6.08 %) for population controls. The com-
bined risk of graft loss and death in RTx recipients
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Table 2 Incidence rates and rate-ratios for pyelonephritis according to the burden of comorbidity
Subgroup CCI-scorea No.b
(%)
PN, hospitalizations, No.c IR(95 % CI) IRR (95 % CI) P value
Renal transplant recipients Low (0) 1,393 (52.5) 131 15.9 (13.4–18.9) 73.5 (56.1–96.3) <.0001
Population controls Low (0) 43,253 (87.9) 88 0.22 (0.18–0.27) 1 (Reference)
Renal transplant recipients Medium (1–2) 707 (26.6) 60 17.8 (13.9–23.0) 36.9 (21.5–63.2) <.0001
Population controls Medium (1–2) 4,954 (10.1) 17 0.48 (0.30–0.78) 1 (Reference)
Renal transplant recipients High≥ 3 556 (20.9) 70 27.9 (22.0–35.2) 16.0 (8.2–31.0) <.0001
Population controls High≥ 3 1,019 (2.1) 10 1.74 (0.94–3.24) 1 (Reference)
Abbreviations: CI confidence interval, IR incidence rate, IRR incidence rate ratio
aLevel of Charlson co-morbidity index score (see text)
bNumber and percentage allocated on the CCI-score
cNo. of Hospitalizations per 1000 person-years
Table 1 Incidence of first hospitalization for pyelonephritis in renal transplant recipients
Characteristic Pyelonephritis Hospitalizations, No.a Person-Years Follow up IR (95 % Cl) IRR (95 % Cl) P* Value
Entire study period (1990–09)
Renal transplant recipients 261 14,121 18.5 (16.4–20.9) 772.0 (57.8–89.7) <.001
Population controls 115 447,976 0.26 (0.21–0.31)
1990–1994:
Renal transplant recipients 35 1,175 30.0 (21.0–42.0) 841 (115–-6138) <.001
Population controls 1 28,218 0.04 (0.01─0.25)
1995–1999:
Renal transplant recipients 67 2,974 23.0 (18.0–29.0) 178 (94.1–337) <.0001
Population controls 11 86,904 0.13 (0.07–0.23)
2000–2004:
Renal transplant recipients 81 4,242 19.0 (15.0–24.0 75.6 (50.8–112) <.0001
Population controls 35 138,543 0.25 (0.18–0.35)
2005–2009:
Renal transplant recipients 78 5,731 14.0 (11.0–17.0) 38.9 (28.1–53.8) <.0001
Population controls 68 194,311 0.35 (0.28–0.44)
Male:
Renal transplant recipients 122 9,373 13.0 (10.9–15.5) 69.4(50.3–95.8) <.0001
Population controls 53 282,662.3 0.19 (0.14–0.25)
Female:
Renal transplant recipients 139 4,747.2 29.3(24.8–34.6) 78.1(57.9–105) <.0001
Population controls 62 165,314.9 0.38(0.29─0.48)
<50 years
Renal transplant recipients 140 7,696 18.2(15.4–21.5) 117 (79.8–170) <.0001
Population controls 33 211,410 0.16(0.11–0.22)
50–65 years:
Renal transplant recipients 98 5,235 18.7(15.4–22.8) 81.7 (56.8–118) <.0001
Population controls 41 178,960 0.23(0.17–0.31)
65 + years:
Renal transplant recipients 23 1,190 19.3(12.8–29.1) 127.2 (16.3–45.2) <.0001
Population controls 41 57,607 0.71(0.52–0.97)
Abbreviations: Cl confidence interval, IR incidence rate, IRR incidence rate ratio
*P value corresponding to IRR
aNo. of hospitalizations per 1000 person-years
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IRa (95 % CI) Unadjusted
IRR (95 % CI)
Adjustedb
IRR (95 % CI)
P* Value
Recipient gender
Male (122) 13.0 (10.9–15.5) 1 (Reference) 1 (Reference)
Female (139) 29.3 (24.8–34.6) 2.25(1.76–2.87) 2.04(1.59–2.61) <.001
Recipient, CCI-score
Low (0) 131 15.9 (13.4–18.9) 1 (Reference) 1 (Reference)
Medium (1–2) 60 17.8 (13.9–23.0) 1.12 (0.83–1.52) 0.98 (0.71–1.36) .92
High (≥3) 70 27.9 (22.0–35.2) 1.75 (1.31–2.34) 1.96 (1.16–3.31) .01
Donor type
Cadaveric donor 190 19.2 (16.6–22.1) 1 (Reference) 1 (Reference)
Living unrelated donor 22 16.2 (10.7–24.6) 0.85 (0.54–1.32) 1.01 (0.65–1.58) .95
Living related donor 49 17.2 (13.0–22.8) 0.90 (0.66–1.23) 1.00 (0.71–1.39) .98
HLA mismatch
AB mismatchc
<3 122 18.6 (15.5–22.2) 1 (Reference) 1 (Reference)
≥3 46 16.6 (12.4–22.2) 0.90 (0.64–1.26) 0.88 (0.62–1.25) .49
DR mismatchc
<2 46 13.6 (10.2–18.1) 1 (Reference) 1 (Reference)
2 122 20.5 (17.2–24.5) 1.51 (1.07–2.12) 1.54 (1.10–2.18) .01
Cause of ESRD
Glomerulonephritis 46 10.3 (7.7–13.7) 1 (Reference) 1 (Reference)
Diabetes mellitus type 1 53 27.7 (21.2–36.2) 2.69 (1.81–3.40) 1.34 (0.73–2.48) .35
Diabetes mellitus type 2 4 16.8 (6.33–44.9) 1.64 (0.59–4.55) 1.00 (0.33–2.99) 1.00
Chronic interestitial nephritis 44 31.7 (23.6–42.6) 3.08 (2.04–4.66) 2.53 (1.66–3.85) <.001
Hypertensive kidney disease 53 17.6 (13.4–23.0) 1.71 (1.15–2.54) 1.59 (1.06–2.37) .02
Polycystic kidney disease 39 19.2 (14.0–26.3) 1.87 (1.22–2.86) 1.66 (1.07–2.57) .02
Vasculitis 10 33.2 (17.9–61.7) 3.23 (1.63–6.39) 2.61 (1.28–5.30) .01
Unkown 12 15.9 (9.0–28.0) 1.55 (0.82–2.92) 1.18 (0.62–2.27) .62
Posttransplant time
0–6 months 83 69.9(56.4–86.7) 1 (Reference) 1 (Reference)
7–12 months 29 26.9(18.7–38.7) 0.38(0.25–0.59) 0.39(0.25–0.59) <.001
13–24 months 33 16.9 (12.0–23.8) 0.24 (0.16–0.36) 0.24 (0.16–0.37) <.001
+24 months 116 11.7(9.8–14.0) 0.17 (0.13–0.22) 0.18 (0.13–0.24) <.001
Recipient age
<50 years 140 18.2 (15.4–21.5) 1 (Reference) 1 (Reference)
50–65 years 98 18.7 (15.4–22.8) 1.03 (0.79–1.33) 1.06 (0.80–1.41) .68
+65 years 23 19.3 (12.8–29.1) 1.06 (0.68–1.65) 1.21 (0.76–1.93) .43
Calendar period
1990–1994 35 29.8 (21.4–41.5) 1 (Reference) 1 (Reference)
1995–1999 67 22.5 (17.7–28.6) 0.76 (0.50–1.14) 0.73 (0.48–1.12) .16
2000–2004 81 19.1 (15.4–23.7) 0.64 (0.43–0.95) 0.62 (0.41–0.94) .02
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following an episode of pyelonephritis compared to
those with no admission due to pyelonephritis was
1.22 fold (CI: 1.01–1.48) (Table 4). In addition, when
the first 90 days posttransplantation were censored to
eliminate the bias from early graft loss/death follow-
ing transplantation, an episode of pyelonephritis was
associated with a 45 % higher risk of graft loss and
death (IRR = 1.45, CI: 1.19–1.77) (Table 4).
Validation of discharge diagnosis of pyelonephritis
We reviewed a random sample of 75 medical records
with a discharge diagnosis of pyelonephritis. The per-
centage of episodes recorded in the DNPR fulfilling the
criteria for pyelonephritis was 76 % (57/75).
Discussion
In the present study we found that RTx recipients had a
72-fold higher risk of first-time hospitalisation for pyelo-
nephritis compared to matched population controls.
Even when adjusting for potential confounders including
calendar period, age, gender and CCI score, the risk of
pyelonephritis remained highly elevated during the en-
tire study period in RTx recipients. Although the inci-
dence of hospitalisation for pyelonephritis decreased by
more than 50 % during the study period our findings
confirm that pyelonephritis is a common cause of hospi-
talisation after renal transplantation. In addition, we
found that the combined risk of graft loss and death was
increased by 45 % in RTx recipients following an episode
of pyelonephritis compared to those with no admission
due to pyelonephritis. These interesting findings high-
light the potential for improving the prognosis in renal
transplant recipients by further reducing the risk of
pyelonephritis.
To our knowledge, this study is among the first to in-
vestigate the burden of pyelonephritis among RTx recipi-
ents and the impact of pyelonephritis on renal graft
survival and mortality in a nationwide population based
setting over a 20-year period. The strengths of our study
include the use of population-based, nationwide cohorts
with inclusion of all adult (from 16-years), first-time RTx
recipients, minimal loss to follow-up, long study period,
and the availability of comprehensive hospitalisation
data. The CCI-score enabled us to adjust for underlying
diseases, and the large study size yielded estimates with
high statistical precision.
The impact of pyelonephritis on graft and patient sur-
vival is debated. While short term mortality was low, we
found that hospitalisation for pyelonephritis in RTx re-
cipients was associated with persistent increased risk of
graft loss and death. Pellé et al. [16] also found post-
transplant pyelonephritis to be an independent risk fac-
tor for worse long-term graft survival but found no asso-
ciation with mortality. A study by Giral et al. [17] also
suggested that post-transplant pyelonephritis was linked
to decreased graft survival. However, this was only the
case when pyelonephritis occurred during the first three
months post-transplantation. Contrary to Giral et al. a
retrospective study by Abbott et al. [18] showed that
UTI appearing more than six months after renal trans-
plantation was independently associated with worse long
term patient survival and risk of graft loss among RTx
recipients. However, this study had some limitations,
i.e.,co-morbidities were not taken into account. This
Table 3 Incidence of first hospitalization for pyelonephritis in renal transplant recipients according to potential risk factors for
pyelonephritis (Continued)
2005–2009 78 13.6 (10.9–17.0) 0.46 (0.31–0.68) 0.42 (0.27–0.64) <.001
Abbreviations: CI confidence interval, ESRD end-stage renal disease, HLA leukocyte antigen, IR incidence rate, IRR incidence rate ratio, CCI-score Charlson co-
morbidity index score
*Pvalue corresponding to the adjusted IRR
aNo. of Hospitalizations per 1000 person-years
b Adjusted for all other variables
cMissing values not shown
Table 4 The effect of pyelonephritis on combined endpoint graft function and mortality
Time at riska No. of Pyelonephritis IRb (95 % CI) IRRe (95 % CI) p-value*
+ 0 daysc 0 7.54 (7.10–8.01) 1 (reference)
1 9.01 (7.52–10.8) 1.22 (1.01–1.48) .043
+ 90 daysd 0 6.41 (6.00–6.85) 1 (reference)
1 8.97 (7.49–10.7) 1.45 (1.19–1.77) ≤.001
Abbreviations: No. number, CI confidence interval, IR incidence rate, IRR incidence rate ratio
*P value corresponding to the IRR
atime of risk = posttransplant time
bIR per 100 person-years
cTime at risk begins from the day the person is diagnosed with pyelonephritis
dThe first 90 days post-transplantation are sensored
eAdjusted for sex and age
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may have affected the findings. Thus, it seems difficult
to conclude whether UTI was the primary cause of graft
loss and death or merely a marker of morbidity.
Chuang et al. [4] also showed that UTI was significantly
associated with increased mortality; contrary to Abbott et
al. UTI did not increase the risk of renal graft loss. How-
ever, the results were not adjusted for co-morbidities and
UTI was probably more frequent in the RTx recipients
with significant co-morbidities. The above findings are in
contrast to Rao KV et al. [19] who showed that late-onset
post-transplant UTI is a benign condition.
The above mentioned studies are characterised by
somewhat conflicting data. To some degree, this can be
explained by “UTI” referring to different conditions in
the urinary system, some mainly involving the lower
UTIs and some the upper UTIs. Altogether, the major-
ity of studies including ours indicate that severe UTI
(e.g., requiring hospitalization) has a negative impact
on graft survival and mortality in RTx recipients.
We also found that the incidence of first-time hospital-
isation for pyelonephritis among RTx recipients declined
throughout the study period. The reason for this finding is
not unambiguous but might be explained by early detec-
tion of lower UTIs and treatment prior to development of
pyelonephritis. In addition, improved per-operative anti-
biotic prophylaxis, aseptic surgery, invasive procedures
and earlier removal of bladder catheters may have contrib-
uted. On the contrary, ureteric stents were likely used less
frequently at the beginning of the period, but removal of
the stents was probably performed earlier by the end of
the study period. In addition, there has been a trend to-
wards lower doses of prednisolone in RTx during the
study period, which may reduce the risk of UTI. These po-
tential changes could have contributed to the observed
changes in IR, but data was not available.
In our study we found no association between diabetes
mellitus and increased risk of UTI in RTx recipients; this
is in agreement with some previous studies [4, 9, 20]
but, whereas others have reported that diabetes mellitus
increased the risk of developing UTI in RTx recipients
[10, 21, 22]. In our analysis, we only studied the effect of
diabetes in patients with diabetes as a cause of ESRD
and thus, some patients who had other causes of ESRD
may also have had diabetes. However, this proportion of
“unregistered” diabetes would likely be low and is un-
likely to have a significant effect on the risk estimate.
Chuang et al. and Dantes et al. found receiving an organ
transplant from deceased donor was independently asso-
ciated with an increased risk of post-transplant UTI.
However, we did not find this association in our present
study or in previous studies looking at infection-risk in
transplant recipients [23, 24].
Our study also had some limitations. Coding errors
may occur in routine hospital discharge data leading to
misclassification of pyelonephritis in both RTx recipients
and the general population. Differential misclassification
may bias the relative risk estimates; however, according
to our diagnosis validation, the degree of misclassifica-
tion was relative low (the positive predictive value of a
pyelonephritis discharge diagnosis was 76 % in our
study, which is acceptable and in line with other valid-
ation studies). While we did not have access to the
remaining patients medical records, we consider our val-
idation sample representative for the remaining study
population since coding of discharge diagnoses is ge-
nerally considered uniform throughout Denmark. In
addition, doctors may have a lower threshold for hospital
admission of RTx recipients with signs and symptoms of
pyelonephritis causing us to overestimate the relative
risk of pyelonephritis in RTx recipients. In addition, the
threshold for hospitalisation may have changed over
time in both groups. Another possible limitation of our
study was that we lacked information on some potential
risk factors for pyelonephritis such as immunosuppres-
sive regimens and the use of ureteral stents. Inte-
restingly, Snyder et al. only found a weak association
between steroid use, immune suppressive regimens and
first bacterial infections in United States RTx recipients
which suggest that the impact of these limitations is
limited [25].
Conclusion
Though the risk of first-time hospitalisation for pyeloneph-
ritis declined throughout our study period, pyelonephritis is
still a frequent infection after renal transplantation, espe-
cially in the first six months post-transplantation and
among female transplant recipients. In addition, our find-
ings indicate that pyelonephritis may increase the risk of
graft loss and mortality emphasising the importance of pre-
ventive measures as well as early detection and treatment
of UTI in RTx recipients.
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